



# Cardiologists Unified in Building Excellence in Diabetes

Friday, October 25, 2019

2019 Canadian Cardiovascular Congress, Montreal

**ATTENTION:** CARDIOLOGISTS, CARDIAC SURGEONS, ENDOCRINOLOGISTS, NEPHROLOGISTS, INTERNISTS, PRIMARY CARE PHYSICIANS, NURSES AND ALLIED HEALTH PROFESSIONALS INVOLVED IN CARDIOVASCULAR PATIENT CARE

## FACULTY



CO-CHAIR

**Lawrence A. Leiter**  
MD, FRCPC, FACP, FACE, FAHA, FACC


Endocrinologist,  
St. Michael's Hospital;  
Professor of Medicine and  
Nutritional Sciences,  
University of Toronto,  
Toronto, ON



CO-CHAIR

**Subodh Verma**  
MD, PhD, FRCSC, FAHA

Cardiac Surgeon,  
St. Michael's Hospital;  
Professor of Surgery and,  
Pharmacology and Toxicology,  
University of Toronto;  
Canada Research Chair in  
Cardiovascular Surgery,  
Toronto, ON




**Vineeta Ahooja,**  
MD, FACC, FASE

Advanced Cardiac Imaging  
Cardiovascular Medicine,  
The Heart Health Institute  
Toronto, ON



**Deepak L. Bhatt**  
MD, MPH, FACC, FAHA, FSCAI, FESC

Cardiologist,  
Executive Director of Interventional  
Cardiovascular Programs,  
Brigham and Women's Hospital  
Heart & Vascular Center;  
Professor of Medicine,  
Harvard Medical School,  
Boston, MA



**Michael E. Farkouh**  
MD, MSc, FRCPC, FACC, FAHA

Cardiologist, Peter Munk Chair in  
Multinational Clinical Trials,  
Peter Munk Cardiac Centre;  
Director, Heart and Stroke Richard  
Lewar Centre of Excellence;  
Professor and Vice Chair Research,  
Department of Medicine,  
University of Toronto,  
Toronto, ON




**Ronald M. Goldenberg**  
MD, FRCPC, FACE

Consultant Endocrinologist,  
North York General Hospital,  
LMC Diabetes & Endocrinology,  
Toronto, ON



**G. B. John Mancini**  
MD, FRCPC, FACP, FACC

Professor of Medicine,  
Director, Cardiovascular Imaging  
Research Core Laboratory (CIRCL)  
University of British Columbia;  
Cardiologist, Cardiac Computed  
Tomographic Angiography  
Program, Vancouver General  
Hospital; Cardiologist, St. Paul's  
Hospital, Vancouver, BC



**Eileen O'Meara,**  
MD, FRCPC

Cardiologist,  
Montreal Heart Institute;  
Professor of Medicine,  
Université de Montréal,  
Montréal, QC



**Scott D. Solomon**  
MD, FACC, FHFA

Cardiologist, Edward D. Frohlich  
Distinguished Chair,  
Professor of Medicine,  
Harvard Medical School;  
Director, Noninvasive Cardiology,  
Brigham and Women's Hospital,  
Boston, MA



**Jordan J. Weinstein**  
MD, FRCP(c)

Nephrologist,  
St. Michael's Hospital;  
Assistant Professor of Medicine,  
University of Toronto,  
Toronto, ON

## LEARNING OBJECTIVES

At the conclusion of this session, participants will be able to:

1. Describe the cardio-renal spectrum in type 2 diabetes (T2D)
2. Differentiate between the cardiovascular outcome trials in T2D
3. Implement the recommendations of clinical practice guidelines and translate recent clinical trial evidence into risk-reduction approaches in T2D
4. Develop partnerships across the continuum of patient care to promote shared decision making for patients who have T2D

This event is an accredited Group Learning Activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society.

This program was co-developed with the Canadian Cardiovascular Society and was planned to achieve scientific integrity, objectivity and balance.

Attendance at this exciting program requires registration to the Canadian Cardiovascular Congress — meaning you'll have access to outstanding programming, including plenary and CCS guideline sessions, e-posters, the exhibit hall and more.

Flexible registration options are available.  
For more information contact  
[congress@ccs.ca](mailto:congress@ccs.ca)



CANADIAN  
CARDIOVASCULAR  
CONGRESS

CONGRÈS CANADIEN  
SUR LA SANTÉ  
CARDIOVASCULAIRE


To register go to:  
<http://cardiocongress.org/en/registration.html>

# CUBED

## Cardiologists Unified in Building Excellence in Diabetes

Friday, October 25, 2019

2019 Canadian Cardiovascular Congress, Montreal



### AGENDA

PART I Moderators: Dr. Lawrence Leiter and Dr. Eileen O'Meara		LEARNING OBJECTIVES
9:00 am	Opening remarks and objectives - Dr. Lawrence A. Leiter	
9:05 am	<b>CVOTs with glucose-lowering agents:</b> Key take aways for cardiologists - Dr. Lawrence A. Leiter	<ul style="list-style-type: none"> <li>To describe the rationale behind the CVOTs</li> <li>To recall the study populations and results of the CVOTs that led to guideline change</li> </ul>
9:20 am	<b>GLP-1 receptor agonists and atherosclerosis:</b> The latest clinical trial evidence - Dr. Michael E. Farkouh	<ul style="list-style-type: none"> <li>To compare the recent GLP-1RA trial results with those already reported</li> <li>To discuss how these new data may impact on clinical practice and patient choice</li> </ul>
9:35 am	<b>The cardiorenal interface of diabetes:</b> Clinical trials update - Dr. Jordan J. Weinstein	<ul style="list-style-type: none"> <li>To outline how CV and renal function drive therapeutic decisions in diabetes</li> <li>To summarize the renal outcomes of the CVOTs and a SGLT2 inhibitor renal outcome trial</li> </ul>
9:50 am	Q&A	
10:00 am	Health break/Meet the speaker	
PART II Moderators: Dr. Subodh Verma and Dr. Vineeta Ahooja		
10:30 am	<b>A novel role of EPA in diabetes:</b> Casting another light on triglycerides - Dr. Deepak L. Bhatt	<ul style="list-style-type: none"> <li>To recap the relationship between triglycerides and the risk for ASCVD</li> <li>To review the newest data on adjunct EPA therapy in diabetes</li> </ul>
10:45 am	<b>Diabetes, SGLT2i and heart failure:</b> An essential primer - Dr. Subodh Verma	<ul style="list-style-type: none"> <li>To recognize that HF is a clinically significant comorbidity in diabetes</li> <li>To highlight the latest trial findings on SGLT2 inhibition in HF</li> </ul>
11:00 am	<b>HFpEF in diabetes</b> - Dr. Scott D. Solomon	<ul style="list-style-type: none"> <li>To detail the different types of heart failure</li> <li>To communicate the emerging trial data on novel HF therapies in diabetes</li> </ul>
11:15 am	<b>Integrating science and guidelines into a practical call to action for cardiovascular specialists:</b> An interactive case-based discussion - Dr. Ronald M. Goldenberg Dr. G.B. John Mancini, and Dr. Eileen O'Meara	<ul style="list-style-type: none"> <li>To interpret how the CVOT data may be translated to people with type 2 diabetes, with and without ASCVD</li> <li>To infer how the guidelines may change to accommodate the use of SGLT2 inhibitors beyond type 2 diabetes</li> <li>To determine how to optimize lipid-lowering strategies so as to lower residual risk in people with type 2 diabetes</li> </ul>
11:29 am	Q&A	
11:40 am	Closing remarks - Dr. Subodh Verma	

This program was made possible by educational grants from:



HLS Therapeutics Inc.

